Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

394
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
394
Drug Therapy01:28

Drug Therapy

256
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
256
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

7.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.4K
Molecular and Ionic Solids02:54

Molecular and Ionic Solids

20.0K
Crystalline solids are divided into four types: molecular, ionic, metallic, and covalent network based on the type of constituent units and their interparticle interactions.
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
20.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.

Clinical pharmacokinetics·2026
Same author

Indirect calorimetry in oncology: A case-based clinical tutorial.

Clinical nutrition ESPEN·2026
Same author

[Metabolic and cardiovascular disorders with lorlatinib: How to detect and manage them in practice?]

Bulletin du cancer·2026
Same author

18F-fluorodeoxyglucose PET/CT uptake characteristics in immune checkpoint inhibitor-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumatica.

Rheumatology (Oxford, England)·2026
Same author

Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studies.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction.

The oncologist·2026

Related Experiment Video

Updated: Jan 23, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.6K

Drug interactions with solid tumour-targeted therapies.

Audrey Thomas-Schoemann1, Benoit Blanchet1, Christophe Bardin2

  • 1Centre d'Étude et de Recours aux Inhibiteurs de l'Angiogénèse, Paris, France; UF de Pharmacocinétique et Pharmacochimie, Groupement des Hôpitaux Paris Centre, 75014 Paris, France.

Critical Reviews in Oncology/Hematology
|September 18, 2013
PubMed
Summary

Drug interactions involving targeted cancer therapies like TKIs and mTOR inhibitors are a significant clinical concern, particularly with polypharmacy in elderly patients. Understanding these interactions is crucial to manage anticancer drug exposure and prevent resistance or toxicity.

Keywords:
5-fluorouracile5FUABCATP-binding cassetteAUCBCRPC(max)CYPDDIDrug–drug interactionsEIAEDSHerb–drug interactionsMammalian target of rapamycin inhibitorsP-glycoproteinP-gpPharmacokineticsSolid tumourTKITargeted therapiesTyrosine kinase inhibitorsUDP-glucuronyl transferaseUGTarea under the curvebreast cancer resistance proteincytochrome p450 enzymesdrug–drug interactionsenzyme-inducing antiepileptic drugsmTORmammalian target of rapamycinmaximum (peak) plasma concentrationtyrosine kinase inhibitor

More Related Videos

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.2K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Related Experiment Videos

Last Updated: Jan 23, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.6K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.2K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Metabolism

Background:

  • Drug interactions (DDIs) pose a significant challenge in cancer treatment, especially with targeted therapies.
  • Polypharmacy in elderly patients with cancer and comorbidities increases the risk of DDIs.
  • Tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors are primarily metabolized by cytochrome P450 enzymes, heightening DDI risks.

Purpose of the Study:

  • To provide a comprehensive review of DDIs involving FDA-approved targeted therapies for solid tumors.
  • To examine interactions between targeted anticancer drugs and medicinal herbs or other drugs.
  • To offer clinical practice guidelines for oncologists and pharmacists managing these interactions.

Main Methods:

  • Systematic review of existing literature on drug-drug interactions.
  • Focus on targeted therapies approved by the FDA for over three years.
  • Inclusion of interactions with medicinal herbs and other commonly used drugs.

Main Results:

  • Identified key DDIs associated with specific targeted therapies (sorafenib, sunitinib, erlotinib, gefitinib, imatinib, lapatinib, everolimus, temsirolimus).
  • Highlighted how DDIs can alter anticancer drug exposure, potentially leading to resistance or toxicity.
  • Cataloged interactions involving cytochrome P450 metabolism.

Conclusions:

  • Managing DDIs is critical for optimizing cancer treatment outcomes with targeted therapies.
  • Awareness of potential interactions with concomitant medications and herbal products is essential.
  • Guidelines are provided to assist healthcare professionals in clinical decision-making regarding DDIs in cancer patients.